The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
Three off-the-shelf mRNA therapies join intismeran autogene.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Antibody-drug conjugates hitting this target abound.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
